156 related articles for article (PubMed ID: 22449782)
61. Multivalent, Stabilized Mannose-6-Phosphates for the Targeted Delivery of Toll-Like Receptor Ligands and Peptide Antigens.
Reintjens NRM; Tondini E; Vis C; McGlinn T; Meeuwenoord NJ; Hogervorst TP; Overkleeft HS; Filippov DV; van der Marel GA; Ossendorp F; Codée JDC
Chembiochem; 2021 Jan; 22(2):434-440. PubMed ID: 32864819
[TBL] [Abstract][Full Text] [Related]
62. Antibody co-targeting of DCs.
Zitvogel L; Palucka K
Blood; 2011 Dec; 118(26):6726-7. PubMed ID: 22194392
[No Abstract] [Full Text] [Related]
63. The design of semi-synthetic and synthetic glycoconjugate vaccines.
Costantino P; Rappuoli R; Berti F
Expert Opin Drug Discov; 2011 Oct; 6(10):1045-66. PubMed ID: 22646863
[TBL] [Abstract][Full Text] [Related]
64. Tumor and dendritic cells as cellular vaccines: confrontation and perspectives--a symposium in writing.
Colombo MP
Cancer Immunol Immunother; 1998 Apr; 46(2):69. PubMed ID: 9558000
[No Abstract] [Full Text] [Related]
65. How can we tell when cancer vaccines vaccinate?
Wolchok JD; Chapman PB
J Clin Oncol; 2003 Feb; 21(4):586-7. PubMed ID: 12586792
[No Abstract] [Full Text] [Related]
66. Tumour immunology: A close-range dual hit for tumour immunity.
Leavy O
Nat Rev Immunol; 2012 Feb; 12(4):227. PubMed ID: 22362306
[No Abstract] [Full Text] [Related]
67. Myelin Peptide-Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient.
Matsoukas J; Deraos G; Kelaidonis K; Hossain MK; Feehan J; Tzakos AG; Matsoukas E; Topoglidis E; Apostolopoulos V
Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960201
[TBL] [Abstract][Full Text] [Related]
68. Misguided cancer goal.
Nature; 2012 Nov; 491(7426):637. PubMed ID: 23198300
[No Abstract] [Full Text] [Related]
69. Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414863
[No Abstract] [Full Text] [Related]
70. Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.
Zom GG; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
Oncoimmunology; 2014; 3(7):e947892. PubMed ID: 25610736
[TBL] [Abstract][Full Text] [Related]
71. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.
Lynn GM; Sedlik C; Baharom F; Zhu Y; Ramirez-Valdez RA; Coble VL; Tobin K; Nichols SR; Itzkowitz Y; Zaidi N; Gammon JM; Blobel NJ; Denizeau J; de la Rochere P; Francica BJ; Decker B; Maciejewski M; Cheung J; Yamane H; Smelkinson MG; Francica JR; Laga R; Bernstock JD; Seymour LW; Drake CG; Jewell CM; Lantz O; Piaggio E; Ishizuka AS; Seder RA
Nat Biotechnol; 2020 Mar; 38(3):320-332. PubMed ID: 31932728
[TBL] [Abstract][Full Text] [Related]
72. Challenges in developing personalized neoantigen cancer vaccines.
Katsikis PD; Ishii KJ; Schliehe C
Nat Rev Immunol; 2024 Mar; 24(3):213-227. PubMed ID: 37783860
[TBL] [Abstract][Full Text] [Related]
73. Induction of broad multifunctional CD8+ and CD4+ T cells by hepatitis B virus antigen-based synthetic long peptides
Jansen DTSL; de Beijer MTA; Luijten RJ; Kwappenberg K; Wiekmeijer AS; Kessler AL; Pieterman RFA; Bouzid R; Krebber WJ; de Man RA; Melief CJM; Buschow SI
Front Immunol; 2023; 14():1163118. PubMed ID: 37781393
[TBL] [Abstract][Full Text] [Related]
74. Macrophage-infectivity potentiator of
Radwanska M; de Lemos Esteves F; Linsen L; Coltel N; Cencig S; Widart J; Massart AC; Colson S; Di Paolo A; Percier P; Ait Djebbara S; Guillonneau F; Flamand V; De Pauw E; Frère JM; Carlier Y; Truyens C
Front Immunol; 2023; 14():1138526. PubMed ID: 37033946
[TBL] [Abstract][Full Text] [Related]
75. Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM; Welters MJP; Slingerland M; van Poelgeest MIE; de Vos van Steenwijk PJ; Roozen I; Boekestijn S; Loof NM; Zom GG; Valentijn ARPM; Krebber WJ; Meeuwenoord NJ; Janssen CAH; Melief CJM; van der Marel GA; Filippov DV; van der Burg SH; Gelderblom H; Ossendorp F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36261215
[TBL] [Abstract][Full Text] [Related]
76. Designing AbhiSCoVac - A single potential vaccine for all 'corona culprits': Immunoinformatics and immune simulation approaches.
Choudhury A; Sen Gupta PS; Panda SK; Rana MK; Mukherjee S
J Mol Liq; 2022 Apr; 351():118633. PubMed ID: 35125571
[TBL] [Abstract][Full Text] [Related]
77. CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity.
Long Y; Sun J; Song TZ; Liu T; Tang F; Zhang X; Ding L; Miao Y; Zhu W; Pan X; An Q; Qin M; Tong X; Peng X; Yu P; Zhu P; Xu J; Zhang X; Zhang Y; Liu D; Chen B; Chen H; Zhang L; Xiao G; Zuo J; Tang W; Zhou J; Li H; Xu Z; Zheng HY; Long XY; Qin Q; Gan Y; Ren J; Huang W; Zheng YT; Jin G; Gong L
Cell Discov; 2022 Feb; 8(1):9. PubMed ID: 35102138
[TBL] [Abstract][Full Text] [Related]
78. Proteome-Wide Mapping and Reverse Vaccinology Approaches to Design a Multi-Epitope Vaccine against
Aldakheel FM; Abrar A; Munir S; Aslam S; Allemailem KS; Khurshid M; Ashfaq UA
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696187
[No Abstract] [Full Text] [Related]
79. Lipopeptides for Vaccine Development.
Hamley IW
Bioconjug Chem; 2021 Aug; 32(8):1472-1490. PubMed ID: 34228433
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
